Tetanus

8
Pipeline Programs
3
Companies
14
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
1
0
1
4
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Vaccine
4100%
+ 4 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Sanofi
SanofiPARIS, France
5 programs
1
1
3
Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis AdsorbedPhase 41 trial
Tetanus Toxoid, Diphtheria Toxoid and Pertussis VaccinePhase 4Vaccine1 trial
Tetanus-diphtheria-acellular pertussisPhase 41 trial
TdapPhase 35 trials
Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1Phase 1/2Vaccine1 trial
Active Trials
NCT02587520Completed1,363Est. Feb 2017
NCT06258057Active Not Recruiting365,000Est. Dec 2026
NCT05264662Active Not Recruiting511Est. Jun 2025
+6 more trials
Grifols
GrifolsNEW YORK, NY
1 program
1
Tetanus Immune GlobulinPhase 41 trial
Active Trials
NCT00437671TerminatedEst. Sep 2007
GC Biopharma
GC BiopharmaKorea - Yongin
2 programs
1
1
GC3111 vaccinePhase 2Vaccine1 trial
Biological: GC3111 vaccinePhase 1/2Vaccine1 trial
Active Trials
NCT02813486UnknownEst. Nov 2016
NCT04238975UnknownEst. May 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SanofiTdap
SanofiTetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine
SanofiAdacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed
GrifolsTetanus Immune Globulin
SanofiTetanus-diphtheria-acellular pertussis
SanofiTdap
SanofiTdap
SanofiTdap
SanofiTdap
GC BiopharmaGC3111 vaccine
GC BiopharmaBiological: GC3111 vaccine
SanofiTetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1
SanofiTdap
SanofiTdap

Clinical Trials (14)

Total enrollment: 372,073 patients across 14 trials

NCT05264662SanofiTdap

Pertussis Vaccination Among HIV-infected and HIV-uninfected Pregnant Women

Start: Mar 2022Est. completion: Jun 2025511 patients
Phase 4Active Not Recruiting
NCT01439165SanofiTetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine

Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose

Start: Nov 2011Est. completion: Feb 20171,330 patients
Phase 4Completed
NCT01311557SanofiAdacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed

Study of Adacel® Vaccine Administered to Persons 10 Years of Age

Start: Mar 2011Est. completion: Jan 20121,302 patients
Phase 4Completed
NCT00437671GrifolsTetanus Immune Globulin

Tetanus Immunization in Subjects With No Immunization History or With Tetanus Antibody Levels Below Protective Levels

Start: Mar 2007Est. completion: Sep 2007
Phase 4Terminated
NCT00347958SanofiTetanus-diphtheria-acellular pertussis

Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine

Start: Aug 2006Est. completion: Oct 2008545 patients
Phase 4Completed
NCT02089347SanofiTdap

Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Old

Start: Mar 2014Est. completion: Mar 2015534 patients
Phase 3Completed
NCT00928785SanofiTdap

Study Comparing a Tdap-IPV Combined Vaccine With a Tetanus Monovalent Vaccine in Healthy Adults

Start: Jul 2009Est. completion: Dec 200952 patients
Phase 3Completed
NCT00467519SanofiTdap

Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age

Start: Apr 2007Est. completion: Dec 20091,045 patients
Phase 3Completed
NCT00553228SanofiTdap

Pertussis Maternal Immunization Study

Start: Nov 2007Est. completion: Dec 2015320 patients
Phase 2/3Completed
NCT04238975GC BiopharmaGC3111 vaccine

A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults

Start: Oct 2019Est. completion: May 2021
Phase 2Unknown
NCT02813486GC BiopharmaBiological: GC3111 vaccine

Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine

Start: Jun 2016Est. completion: Nov 2016
Phase 1/2Unknown
NCT02587520SanofiTetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1

Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects

Start: Oct 2015Est. completion: Feb 20171,363 patients
Phase 1/2Completed
NCT03958799SanofiTdap

A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada

Start: Jun 2019Est. completion: Apr 202171 patients
Phase 1Completed
NCT06258057SanofiTdap

Safety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During Pregnancy

Start: Jan 2024Est. completion: Dec 2026365,000 patients
N/AActive Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
Vaccine is the dominant modality (100% of programs)
3 companies competing in this space